142 related articles for article (PubMed ID: 26407364)
1. Use of Live Attenuated Influenza Vaccine in Children With Egg Allergy and Asthma.
Kelso JM
J Pediatric Infect Dis Soc; 2015 Mar; 4(1):81-2. PubMed ID: 26407364
[No Abstract] [Full Text] [Related]
2. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
[TBL] [Abstract][Full Text] [Related]
3. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
Woo EJ; Moro PL; Cano M; Jankosky C
Vaccine; 2017 Oct; 35(42):5618-5621. PubMed ID: 28886946
[TBL] [Abstract][Full Text] [Related]
4. Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia.
Clothier HJ; Crawford N; Russell MA; Buttery JP
Euro Surveill; 2017 May; 22(20):. PubMed ID: 28552101
[TBL] [Abstract][Full Text] [Related]
5. Rapid assessment of enhanced safety surveillance for influenza vaccine.
Alguacil-Ramos AM; Portero-Alonso A; Pastor-Villalba E; Muelas-Tirado J; Díez-Domingo J; Sanchis-Ferrer A; Lluch-Rodrigo JA
Public Health; 2019 Mar; 168():137-141. PubMed ID: 30769245
[TBL] [Abstract][Full Text] [Related]
6. Drug makers' adverse event reports are often incomplete, US report finds.
McCarthy M
BMJ; 2015 Feb; 350():h651. PubMed ID: 25652561
[No Abstract] [Full Text] [Related]
7. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009.
Moro PL; Broder K; Zheteyeva Y; Walton K; Rohan P; Sutherland A; Guh A; Haber P; Destefano F; Vellozzi C
Am J Obstet Gynecol; 2011 Feb; 204(2):146.e1-7. PubMed ID: 20965490
[TBL] [Abstract][Full Text] [Related]
8. Trivalent Influenza Vaccine Adverse Event Analysis Based On MedDRA System Organ Classes Using VAERS Data.
Tao C; Du J; Cai Y; Chen Y
Stud Health Technol Inform; 2015; 216():1076. PubMed ID: 26262375
[TBL] [Abstract][Full Text] [Related]
9. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.
Rosenberg M; Sparks R; McMahon A; Iskander J; Campbell JD; Edwards KM
Vaccine; 2009 Jul; 27(32):4278-83. PubMed ID: 19450636
[TBL] [Abstract][Full Text] [Related]
10. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.
Vellozzi C; Broder KR; Haber P; Guh A; Nguyen M; Cano M; Lewis P; McNeil MM; Bryant M; Singleton J; Martin D; DeStefano F
Vaccine; 2010 Oct; 28(45):7248-55. PubMed ID: 20850534
[TBL] [Abstract][Full Text] [Related]
11. General practice encounters following seasonal influenza vaccination as a proxy measure of early-onset adverse events.
Dey A; Gidding HF; Menzies R; McIntyre P
Vaccine; 2014 Apr; 32(19):2204-8. PubMed ID: 24613527
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of adverse events following vaccination in the French armed forces, 2011-2012.
Mayet A; Duron S; Meynard JB; Koeck JL; Deparis X; Migliani R
Public Health; 2015 Jun; 129(6):763-8. PubMed ID: 25890634
[TBL] [Abstract][Full Text] [Related]
13. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16.
Bricout H; Chabanon AL; Souverain A; Sadorge C; Vesikari T; Caroe TD
Euro Surveill; 2017 May; 22(18):. PubMed ID: 28494843
[TBL] [Abstract][Full Text] [Related]
14. Active SMS-based influenza vaccine safety surveillance in Australian children.
Pillsbury A; Quinn H; Cashman P; Leeb A; Macartney K;
Vaccine; 2017 Dec; 35(51):7101-7106. PubMed ID: 29128379
[TBL] [Abstract][Full Text] [Related]
15. Post-Licensure Surveillance of Trivalent Live-Attenuated Influenza Vaccine in Children Aged 2-18 Years, Vaccine Adverse Event Reporting System, United States, July 2005-June 2012.
Haber P; Moro PL; Cano M; Vellozzi C; Lewis P; Woo EJ; Broder K
J Pediatric Infect Dis Soc; 2015 Mar; 4(1):82-3. PubMed ID: 26407365
[No Abstract] [Full Text] [Related]
16. Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia.
Regan AK; Tracey L; Gibbs R
Vaccine; 2015 Nov; 33(46):6149-51. PubMed ID: 26476362
[TBL] [Abstract][Full Text] [Related]
17. Post-Licensure Surveillance of Trivalent Live-Attenuated Influenza Vaccine in Children Aged 2-18 Years, Vaccine Adverse Event Reporting System, United States, July 2005-June 2012.
Haber P; Moro PL; Cano M; Vellozzi C; Lewis P; Woo EJ; Broder K
J Pediatric Infect Dis Soc; 2015 Sep; 4(3):205-13. PubMed ID: 26407428
[TBL] [Abstract][Full Text] [Related]
18. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
[TBL] [Abstract][Full Text] [Related]
19. Web-based intensive monitoring of adverse events following influenza vaccination in general practice.
van Balveren-Slingerland L; Kant A; Härmark L
Vaccine; 2015 May; 33(19):2283-2288. PubMed ID: 25797367
[No Abstract] [Full Text] [Related]
20. [Post-licensure safety surveillance for influenza A(H1N1) pandemic vaccines: first results].
Jacquet A; Ouaret S; Kreft-Jaïs C; Castot A
Rev Prat; 2010 Dec; 60(10):1392-4. PubMed ID: 21425536
[No Abstract] [Full Text] [Related]
[Next] [New Search]
